Risankizumab as a Therapeutic Approach for Recalcitrant Pyoderma Gangrenosum.
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis that is challenging to diagnose and treat. Clinicians frequently use fast-acting corticosteroids, which are subsequently combined with slower-acting immunosuppressants to progressively taper the corticosteroid dosage. Current research is focused...
| Publicado en: | Advances in Skin & Wound Care Vol. 37; no. 5; pp. 276 - 280 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | case study pictorial Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
May2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=177273299&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 177273299 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15277941 38T jtl: Advances in Skin & Wound Care issn: 15277941 maglogo: N pubinfo: dt: May2024 vid: 37 iid: 5 pid: 5086 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 177273299 177273299 177273299 10.1097/ASW.0000000000000129 177273299 ppf: 276 ppct: 4 formats: tig: atl: Risankizumab as a Therapeutic Approach for Recalcitrant Pyoderma Gangrenosum. aug: au: Michelucci, Alessandra Manzo Margiotta, Flavia Granieri, Giammarco Salvia, Giorgia Fidanzi, Cristian Bevilacqua, Matteo Panduri, Salvatore Romanelli, Marco Dini, Valentina affil: Dermatology Resident, Department of Dermatology, University of Pisa, Italy sug: subj: Pyoderma Gangrenosum Drug Therapy Wounds, Chronic Drug Therapy Wounds, Chronic Therapy Pyoderma Gangrenosum Therapy Antibodies, Monoclonal Therapeutic Use Methylprednisolone Therapeutic Use Wound Care Female Adult Middle Age Pyoderma Gangrenosum Pathology Antibodies, Monoclonal Administration and Dosage Prednisone Administration and Dosage Drug Tapering Autolytic Debridement Adrenal Cortex Hormones Therapeutic Use Lidocaine Administration and Dosage Methylprednisolone Administration and Dosage Drugs, Off-Label Drug Therapy, Combination Treatment Outcomes Adult: 19-44 years Middle Aged: 45-64 years Female ab: Pyoderma gangrenosum (PG) is a neutrophilic dermatosis that is challenging to diagnose and treat. Clinicians frequently use fast-acting corticosteroids, which are subsequently combined with slower-acting immunosuppressants to progressively taper the corticosteroid dosage. Current research is focused on the use of monoclonal antibodies (mAbs) directed against target molecules involved in the pathogenesis of PG. However, available data on their efficacy are based on sporadic case reports and clinical experiences, so the authors aimed to evaluate the efficacy of risankizumab, an anti-interleukin-23 mAb, in the management of two complex PG cases. The authors enrolled two patients with PG who were already treated with immunosuppressive therapies. Their management was based on the off-label use of an mAb directed against the p19 subunit of interleukin-23: risankizumab. Patients received subcutaneous injections of 150 mg at the start of treatment, at week 4, and then every 10 weeks thereafter. Systemic therapy was combined with local management of ulcers, based on the principles of TIME (tissue, infection, moisture balance, and epithelialization) applied to the inflammatory and noninflammatory phases of PG. Clinical resolution was obtained at week 24 for patient 1 and week 16 for patient 2 and was maintained until week 40, without adverse effects or disease recurrence. These clinical cases demonstrate that risankizumab is a valid tool in terms of efficacy and safety for complicated cases of multirefractory PG when provided in parallel with local personalized wound management. pubtype: Academic Journal doctype: case study pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|